miRNAs as attractive diagnostic and therapeutic targets for Familial Mediterranean Fever

References

• Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61(10):1447–53.
   PubMed Web of Science ®Google Scholar
• Jesus AA, Fujihira E, Watase M, Terreri MT, Hilario MO, Carneiro-Sampaio M, et al. Hereditary autoinflammatory syndromes: a Brazilian multicenter study. J Clin Immunol. 2012;32(5):922–32.
   PubMed Web of Science ®Google Scholar
• Migita K, Asano T, Sato S, Koga T, Fujita Y, Kawakami A. Familial Mediterranean fever: overview of pathogenesis, clinical features and management. Immunol Med. 2018;41(2):55–61.
   PubMedGoogle Scholar
• Ozcakar ZB, Yalcinkaya F, Yuksel S, Acar B, Gokmen D, Ekim M. Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin Rheumatol. 2006;25(2):149–52.
   PubMed Web of Science ®Google Scholar
• Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302.
   PubMed Web of Science ®Google Scholar
• French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17(1):25–31.
   PubMed Web of Science ®Google Scholar
• Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997;90(4):797–807.
   Google Scholar
• de Torre-Minguela C, Mesa Del Castillo P, Pelegrin P. The NLRP3 and Pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol. 2017;8:43.
   PubMed Web of Science ®Google Scholar
• Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009;60(6):1851–61.
   PubMedGoogle Scholar
• Alvarez-Errico D, Vento-Tormo R, Ballestar E. Genetic and epigenetic determinants in autoinflammatory diseases. Front Immunol 2017;8:318.
   PubMed Web of Science ®Google Scholar
• Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1–10.
   PubMedGoogle Scholar
• Su Z, Yang Z, Xu Y, Chen Y, Yu Q. MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget. 2015;6(11):8474–90.
   PubMedGoogle Scholar
• Zhang L, Wu H, Zhao M, Chang C, Lu Q. Clinical significance of miRNAs in autoimmunity. J Autoimmun. 2020;109:102438.
   PubMed Web of Science ®Google Scholar
• Amarilyo G, Pillar N, Ben-Zvi I, Weissglas-Volkov D, Zalcman J, Harel L, et al. Analysis of microRNAs in familial Mediterranean fever. PLOS One. 2018;13(5):e0197829.
   PubMed Web of Science ®Google Scholar
• Hortu HO, Karaca E, Sozeri B, Gulez N, Makay B, Gunduz C, et al. Evaluation of the effects of miRNAs in familial Mediterranean fever. Clin Rheumatol. 2019;38(3):635–43.
   PubMed Web of Science ®Google Scholar
• DemIr F, Ceb IA, Kalyoncu M. Assessment of circulating microribonucleic acids in patients with familial Mediterranean fever. Arch Rheumatol. 2020;35(1):52–9.
   PubMed Web of Science ®Google Scholar
• Koga T, Migita K, Sato T, Sato S, Umeda M, Nonaka F, et al. MicroRNA-204-3p inhibits lipopolysaccharide-induced cytokines in familial Mediterranean fever via the phosphoinositide 3-kinase γ pathway. Rheumatology. 2018;57(4):718–26.
   PubMed Web of Science ®Google Scholar
• Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007;14(8):1457–66.
   PubMed Web of Science ®Google Scholar
• Chae JJ, Aksentijevich I, Kastner DL. Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol. 2009;146(5):467–78.
   PubMed Web of Science ®Google Scholar
• Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The pyrin inflammasome in health and disease. Front Immunol 2019;10:1745.
   PubMedGoogle Scholar
• Sarı İ, Birlik M, Kasifoğlu T. Familial Mediterranean fever: an updated review. Eur J Rheumatol. 2014;1(1):21–33.
   PubMedGoogle Scholar
• Ozdogan H, Ugurlu S. Familial Mediterranean fever. Presse Med. 2019;48(1 Pt 2):e61–e76.
   PubMed Web of Science ®Google Scholar
• Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I. INFEVERS: the registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res. 2003;31(1):282–5.
   PubMed Web of Science ®Google Scholar
• Shinar Y, Obici L, Aksentijevich I, Bennetts B, Austrup F, Ceccherini I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis. 2012;71(10):1599–605.
   PubMed Web of Science ®Google Scholar
• Marek-Yagel D, Bar-Joseph I, Pras E, Berkun Y. Is E148Q a benign polymorphism or a disease-causing mutation? J Rheumatol. 2009;36(10):2372.
   PubMed Web of Science ®Google Scholar
• Naimushin A, Lidar M, Ben Zvi I, Livneh A. The structural effect of the E148Q MEFV mutation on the pyrin protein: a study using a quantum chemistry model. Isr Med Assoc J. 2011;13(4):199–201.
   PubMed Web of Science ®Google Scholar
• Padeh S, Livneh A, Pras E, Shinar Y, Lidar M, Feld O, et al. Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol. 2010;37(4):865–9.
   PubMed Web of Science ®Google Scholar
• Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H, et al. Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. Rheumatology. 2014;53(4):741–5.
   PubMed Web of Science ®Google Scholar
• Akpolat T, Ozkaya O, Ozen S. Homozygous M694V as a risk factor for amyloidosis in Turkish FMF patients. Gene. 2012;492(1):285–9.
   PubMed Web of Science ®Google Scholar
• Dewalle M, Domingo C, Rozenbaum M, Ben-Chetrit E, Cattan D, Bernot A, et al. Phenotype-genotype correlation in Jewish patients suffering from familial Mediterranean fever (FMF). Eur J Hum Genet. 1998;6(1):95–7.
   PubMed Web of Science ®Google Scholar
• Tunca M, Akar S, Onen F, Ozdogan H, Kasapcopur O, Yalcinkaya F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine. 2005;84(1):1–11.
   PubMed Web of Science ®Google Scholar
• Yalçinkaya F, Cakar N, Misirlioğlu M, Tümer N, Akar N, Tekin M, et al. Genotype-phenotype correlation in a large group of Turkish patients with familial Mediterranean fever: evidence for mutation-independent amyloidosis. Rheumatology. 2000;39(1):67–72.
   PubMed Web of Science ®Google Scholar
• Padeh S, Shinar Y, Pras E, Zemer D, Langevitz P, Pras M, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with familial Mediterranean fever. J Rheumatol. 2003;30(1):185–90.
   PubMed Web of Science ®Google Scholar
• Cazeneuve C, Hovannesyan Z, Genevieve D, Hayrapetyan H, Papin S, Girodon-Boulandet E, et al. Familial Mediterranean fever among patients from Karabakh and the diagnostic value of MEFV gene analysis in all classically affected populations. Arthritis Rheum. 2003;48(8):2324–31.
   PubMedGoogle Scholar
• Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009;60(6):1862–6.
   PubMedGoogle Scholar
• Fujikura K. Global epidemiology of Familial Mediterranean fever mutations using population exome sequences. Mol Genet Genomic Med. 2015;3(4):272–82.
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Brandt B, Berkun Y, Lidar M, Livneh A. The relative contribution of environmental and genetic factors to phenotypic variation in familial Mediterranean fever (FMF). Gene. 2012;491(2):260–3.
   PubMed Web of Science ®Google Scholar
• Berkun Y, Karban A, Padeh S, Pras E, Shinar Y, Lidar M, et al. NOD2/CARD15 gene mutations in patients with familial Mediterranean fever. Semin Arthritis Rheum. 2012;42(1):84–8.
   PubMed Web of Science ®Google Scholar
• Marek-Yagel D, Berkun Y, Padeh S, Lidar M, Shinar Y, Bar-Joseph I, et al. Role of the R92Q TNFRSF1A mutation in patients with familial Mediterranean fever. Arthritis Care Res. 2010;62(9):1294–8.
   Web of Science ®Google Scholar
• Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65.
   PubMed Web of Science ®Google Scholar
• Malumbres M. miRNAs and cancer: an epigenetics view. Mol Aspects Med. 2013;34(4):863–74.
   PubMed Web of Science ®Google Scholar
• Zealy RW, Wrenn SP, Davila S, Min KW, Yoon JH. microRNA-binding proteins: specificity and function. Wiley Interdiscip Rev RNA. 2017;8:e1414.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
   PubMed Web of Science ®Google Scholar
• Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.
   PubMed Web of Science ®Google Scholar
• Tan CL, Plotkin JL, Veno MT, von Schimmelmann M, Feinberg P, Mann S, et al. MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science. 2013;342(6163):1254–8.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. Embo J. 2004;23(20):4051–60.
   PubMed Web of Science ®Google Scholar
• Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597–610.
   PubMed Web of Science ®Google Scholar
• Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6(5):376–85.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res. 2004;32(16):4776–85.
   PubMed Web of Science ®Google Scholar
• Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803(11):1231–43.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Tonevitsky AG, Burwinkel B. Extracellular miRNA: a collision of two paradigms. Trends Biochem Sci. 2016;41(10):883–92.
   PubMed Web of Science ®Google Scholar
• Bayraktar R, Van Roosbroeck K, Calin GA. Cell-to-cell communication: microRNAs as hormones. Mol Oncol. 2017;11(12):1673–86.
   PubMed Web of Science ®Google Scholar
• Maia J, Caja S, Strano Moraes MC, Couto N, Costa-Silva B. Exosome-based cell-cell communication in the tumor microenvironment. Front Cell Dev Biol. 2018;6:18.
   PubMed Web of Science ®Google Scholar
• Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, et al. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016;44(8):3865–77.
   PubMed Web of Science ®Google Scholar
• Paul P, Chakraborty A, Sarkar D, Langthasa M, Rahman M, Bari M, et al. Interplay between miRNAs and human diseases. J Cell Physiol. 2018;233(3):2007–18.
   PubMed Web of Science ®Google Scholar
• Balci-Peynircioglu B, Akkaya-Ulum YZ, Akbaba TH, Tavukcuoglu Z. Potential of miRNAs to predict and treat inflammation from the perspective of familial Mediterranean fever. Inflamm Res. 2019;68(11):905–13.
   PubMed Web of Science ®Google Scholar
• Akkaya-Ulum YZ, Balci-Peynircioglu B, Karadag O, Eroglu FK, Kalyoncu U, Kiraz S, et al. Alteration of the microRNA expression profile in familial Mediterranean fever patients. Clin Exp Rheumatol 2017;35 Suppl 108(6):90–4.
   PubMed Web of Science ®Google Scholar
• Karpuzoglu EM, Kisla Ekinci RM, Balci S, Bisgin A, Yilmaz M. Altered expression of apoptosis-related, circulating cell-free miRNAs in children with familial Mediterranean fever: a cross-sectional study. Rheumatol Int. 2021;41(1):103–11.
   Web of Science ®Google Scholar
• Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824):608–11.
   PubMed Web of Science ®Google Scholar
• Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58(4):1001–9.
   PubMed Web of Science ®Google Scholar
• Lai NS, Yu HC, Tung CH, Huang KY, Huang HB, Lu MC. The role of aberrant expression of T cell miRNAs affected by TNF-α in the immunopathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):261.
   PubMedGoogle Scholar
• Wada T, Toma T, Matsuda Y, Yachie A, Itami S, Taguchi YH, et al. Microarray analysis of circulating microRNAs in familial Mediterranean fever. Mod Rheumatol. 2017;27(6):1040–6.
   PubMed Web of Science ®Google Scholar
• Latsoudis H, Mashreghi MF, Grun JR, Chang HD, Stuhlmuller B, Repa A, et al. Differential expression of miR-4520a associated with pyrin mutations in familial Mediterranean fever (FMF). J Cell Physiol. 2017;232(6):1326–36.
   PubMed Web of Science ®Google Scholar
• Boxberger N, Hecker M, Zettl UK. Dysregulation of inflammasome priming and activation by microRNAs in human immune-mediated diseases. J Immunol. 2019;202(8):2177–87.
   PubMed Web of Science ®Google Scholar
• Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 2020;6:36.
   PubMed Web of Science ®Google Scholar
• Lopez-Castejon G, Pelegrin P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs. 2012;21(7):995–1007.
   PubMed Web of Science ®Google Scholar
• Bauernfeind F, Rieger A, Schildberg FA, Knolle PA, Schmid-Burgk JL, Hornung V. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol. 2012;189(8):4175–81.
   PubMed Web of Science ®Google Scholar
• Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol. 2012;189(8):3795–9.
   PubMed Web of Science ®Google Scholar
• Xiao L, Jiang L, Hu Q, Li Y. MicroRNA-133b ameliorates allergic inflammation and symptom in murine model of allergic rhinitis by targeting Nlrp3. Cell Physiol Biochem. 2017;42(3):901–12.
   PubMedGoogle Scholar
• Zhang QB, Qing YF, Yin CC, Zhou L, Liu XS, Mi QS, et al. Mice with miR-146a deficiency develop severe gouty arthritis via dysregulation of TRAF 6, IRAK 1 and NALP3 inflammasome. Arthritis Res Ther. 2018;20(1):45.
   PubMedGoogle Scholar
• Lian Z, Lv FF, Yu J, Wang JW. The anti-inflammatory effect of microRNA-383-3p interacting with IL1R2 against homocysteine-induced endothelial injury in rat coronary arteries. J Cell Biochem. 2018;119(8):6684–94.
   PubMed Web of Science ®Google Scholar
• Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221–5.
   PubMed Web of Science ®Google Scholar
• Wang W, Ding XQ, Gu TT, Song L, Li JM, Xue QC, et al. Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377. Free Radic Biol Med. 2015;83:214–26.
   PubMed Web of Science ®Google Scholar
• Long L, Yu P, Liu Y, Wang S, Li R, Shi J, et al. Upregulated microRNA-155 expression in peripheral blood mononuclear cells and fibroblast-like synoviocytes in rheumatoid arthritis. Clin Dev Immunol. 2013;2013:296139.
   PubMedGoogle Scholar
• Wang W, Zhang Y, Zhu B, Duan T, Xu Q, Wang R, et al. Plasma microRNA expression profiles in Chinese patients with rheumatoid arthritis. Oncotarget. 2015;6(40):42557–68.
   PubMedGoogle Scholar
• Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLOS One. 2011;6(9):e24604.
   PubMed Web of Science ®Google Scholar
• Moore CS, Rao VT, Durafourt BA, Bedell BJ, Ludwin SK, Bar-Or A, et al. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol. 2013;74(5):709–20.
   PubMed Web of Science ®Google Scholar
• Szelenberger R, Kacprzak M, Saluk-Bijak J, Zielinska M, Bijak M. Plasma MicroRNA as a novel diagnostic. Clin Chim Acta. 2019;499:98–107.
   PubMed Web of Science ®Google Scholar
• Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007;13(10):1668–74.
   PubMed Web of Science ®Google Scholar
• Kappel A, Keller A. miRNA assays in the clinical laboratory: workflow, detection technologies and automation aspects. Clin Chem Lab Med. 2017;55(5):636–47.
   PubMed Web of Science ®Google Scholar
• Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9(2):276.
   PubMed Web of Science ®Google Scholar
• Bonneau E, Neveu B, Kostantin E, Tsongalis GJ, De Guire V. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. EJIFCC. 2019;30(2):114–27.
   PubMedGoogle Scholar
• Backes C, Meese E, Keller A. Specific miRNA disease biomarkers in blood, serum and plasma: challenges and prospects. Mol Diagn Ther. 2016;20(6):509–18.
   PubMed Web of Science ®Google Scholar
• Maqbool R, Ul Hussain M. MicroRNAs and human diseases: diagnostic and therapeutic potential. Cell Tissue Res. 2014;358(1):1–15.
   PubMed Web of Science ®Google Scholar
• Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA therapeutics in cancer – an emerging concept. EBioMedicine. 2016;12:34–42.
   PubMed Web of Science ®Google Scholar
• Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005–17.
   PubMed Web of Science ®Google Scholar
• Lv W, Fan F, Wang Y, Gonzalez-Fernandez E, Wang C, Yang L, et al. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics. 2018;50(1):20–34.
   PubMed Web of Science ®Google Scholar
• Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478.
   PubMed Web of Science ®Google Scholar
• Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science. 2005;309(5740):1577–81.
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thomsen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36(4):1153–62.
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452(7189):896–9.
   PubMed Web of Science ®Google Scholar
• Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother. 2015;59(1):599–608.
   PubMed Web of Science ®Google Scholar
• Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, et al. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018;183(3):428–44.
   PubMed Web of Science ®Google Scholar
• Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA. 2012;109(26):E1695–704.
   PubMed Web of Science ®Google Scholar
• Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45(2):287–94.
   PubMed Web of Science ®Google Scholar
• Montgomery RL, Yu G, Latimer PA, Stack C, Robinson K, Dalby CM, et al. MicroRNA mimicry blocks pulmonary fibrosis. EMBO Mol Med. 2014;6(10):1347–56.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22.
   PubMed Web of Science ®Google Scholar
• Gallant-Behm CL, Piper J, Lynch JM, Seto AG, Hong SJ, Mustoe TA, et al. A microRNA-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin. J Invest Dermatol. 2019;139(5):1073–81.
   PubMed Web of Science ®Google Scholar
• Tafrihi M, Hasheminasab E. MiRNAs: biology, biogenesis, their web-based tools, and databases. MicroRNA. 2019;8(1):4–27.
   PubMedGoogle Scholar
• Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847–65.
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012;13(5):358–69.
   PubMed Web of Science ®Google Scholar
• Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013;113(8):6207–33.
   PubMed Web of Science ®Google Scholar
• Dangwal S, Bang C, Thum T. Novel techniques and targets in cardiovascular microRNA research. Cardiovasc Res. 2012;93(4):545–54.
   PubMed Web of Science ®Google Scholar
• Metzker ML. Sequencing technologies – the next generation. Nat Rev Genet. 2010;11(1):31–46.
   PubMed Web of Science ®Google Scholar
• Baker M. MicroRNA profiling: separating signal from noise. Nat Methods. 2010;7(9):687–92.
   PubMed Web of Science ®Google Scholar